Assessing the cost effectiveness of pre-exposure prophylaxis for HIV prevention in the US

PharmacoEconomics

Volumn 31, Issue 12, 2013, Pages 1091-1104

  Hellinger, Fred J ^a  

^a AGENCY FOR HEALTHCARE RESEARCH AND QUALITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ISONIAZID; PLACEBO; TENOFOVIR; TENOFOVIR DISOPROXIL;

ARTICLE; CONDOM; COST EFFECTIVENESS ANALYSIS; DISEASE TRANSMISSION; DRUG COST; DRUG WITHDRAWAL; HETEROSEXUAL FEMALE; HETEROSEXUAL MALE; HIGH RISK BEHAVIOR; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMOSEXUAL MALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY DISEASE; LIVER DISEASE; MALARIA; MEN WHO HAVE SEX WITH MEN; NAUSEA; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); SELF CONCEPT; SELF REPORT; SEXUAL BEHAVIOR; SEXUAL INTERCOURSE; SEXUALITY; SIDE EFFECT; TRANSGENDERISM; TUBERCULOSIS; VIRUS LOAD; VOMITING;

ANTI-RETROVIRAL AGENTS; CHEMOPREVENTION; COST-BENEFIT ANALYSIS; HIV INFECTIONS; HUMANS; INCIDENCE; MONTE CARLO METHOD; PREVALENCE; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEXUAL BEHAVIOR; UNITED STATES;

EID: 84890408873     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-013-0111-0     Document Type: Article

References (63)

1. Mathers BM, Degenhardt L, Bucello C, Lemon J, Wiessing L, Hickman M. Mortality among people who inject drugs: a systematic review and meta-analysis. Bull World Health Organ. 2013;91(2):102-23.
2. Schneider G, Juday T, Wentworth C 3rd, Lanes S, Hebden T, Seekins D. Impact of health care payer type on HIV stage of illness at time of initiation of antiretroviral therapy in the USA. AIDS Care. 2013;25(11):1470-6.
3. Dilernia DA, Monaco DC, Cesar C, Krolewiecki AJ, Friedman SR, Cahn P, Salomon H. Estimation of HIV-testing rates to maximize early diagnosis-derived benefits at the individual and population level. PLoS One. 2013;8(1):e53193.
4. Nakagawa F, Lodwick RK, Smith CJ, Smith R, Cambiano V, Lundgren JD, Delpech V, Phillips AN. Projected life expectancy of people with HIV according to timing of diagnosis. AIDS. 2012;26(3):335-43.
5. Hall HI, Song R, Rhodes P, et al. Estimation of HIV incidence in the United States. JAMA. 2008;300:520-9.
6. US Centers for Disease Control and Prevention. Interim guidance for clinicians considering the use of preexposure prophylaxis for the prevention of HIV infection in heterosexually active adults. MMWR Morb Mortal Wkly Rep. 2012;61(31):586-9.
7. Prejean J, Song R, Hernandez A, Ziebell R, Green T, et al. Estimated HIV incidence in the United States, 2006-2009. PLoS ONE. 2011;6(8):e17502.
8. Sullivan PS, Carballo-Diéguez A, Coates T, Goodreau SM, McGowan I, Sanders EJ, Smith A, Goswami P, Sanchez J. Successes and challenges of HIV prevention in men who have sex with men. Lancet. 2012;380(9839):388-99.
9. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493-505.
10. Amico KR, McMahan V, Goicochea P, Vargas L, Marcus JL, Grant RM, et al. Supporting study product use and accuracy in self-report in the iPrEx study: next step counseling and neutral assessment. AIDS Behav. 2012;16(5):1243-59.
11. Cremin I, Alsallaq R, Dybul M, Piot P, Garnett G, Hallett TB. The new role of antiretrovirals in combination HIV prevention: a mathematical modelling analysis. AIDS. 2013;27(3):447-58.
12. HIV Modelling Consortium Treatment as Prevention Editorial Writing Group. HIV treatment as prevention: models, data, and questions - towards evidence-based decision-making. PLoS Med. 2012;9(7):e1001259.
13. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587-99.
14. Cohen J. Breakthrough of the year: HIV treatment as prevention. Science. 2011;34:1628-9.
15. Underhill K. Paying for prevention: challenges to health insurance coverage for biomedical HIV prevention in the United States. Am J Law Med. 2012;38(4):607-66.
16. Gomez GB, Borquez A, Case KK, Wheelock A, Vassall A, Hankins C. The cost and impact of scaling up pre-exposure prophylaxis for HIV prevention: a systematic review of cost-effectiveness modelling studies. PLoS Med. 2013;10(3):e1001401.
17. World Health Organization. Guidance on pre-exposure oral prophylaxis (PrEP) for serodiscordant couples, men and transgender women who have sex with men at high risk of HIV: recommendations for use in the context of demonstration projects. Geneva, Switzerland; 2012.
18. Krakower D, Mayer KH. What primary care providers need to know about preexposure prophylaxis for HIV prevention: a narrative review. Ann Intern Med. 2012;157(7):490-7.
19. Okwundu CI, Uthman OA, Okoromah CA. Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals. Cochrane Database Syst Rev. 2012;(7):CD007189.
20. Karim AQ, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329:1168-74.
21. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367:399-410.
22. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367:423-34.
23. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367:411-22.
24. Microbicide Trials Network. Backgrounder: VOICE - Vaginal and Oral Interventions to Control the Epidemic. National Institute of Allergy and Infectious Diseases (NIH), 18 Nov 2012. (http://www.mtnstopshiv.org/news/ studies/mtn003/backgrounder).
25. Vermund SH, Hayes RJ. Combination prevention: new hope for stopping the epidemic. Curr HIV/AIDS Rep. 2013;10(2):169-86.
26. Hankins CA, Dybul MR. The promise of pre-exposure prophylaxis with antiretroviral drugs to prevent HIV transmission: a review. Curr Opin HIV AIDS. 2013;8(1):50-8.
27. Stanley EA. Social networks and mathematical modeling. Connections. 2006;27(1):43-9.
28. Hyman JM, Stanley EA. Using mathematical models to understand the AIDS epidemic. Math Biosci. 1988;90:415-73.
29. Juusola JL, Brandeau ML, Long EF, Owens DK, Bendavid E. The cost-effectiveness of symptom-based and routine screening for acute HIV infection in men who have sex with men in the USA. AIDS. 2011;25:1779-87.
30. Vallabhaneni S, et al. Seroadaptive behavior: association with seroconversion among HIV-MSM. In: Nineteenth Conference on Retroviruses and Opportunistic Infections (CROI), Seattle [abstract 140]; 2012 (the abstract is available on the official conference website)
31. Baggaley RF, Fraser C. Modelling sexual transmission of HIV: testing the assumptions, validating the predictions. Curr Opin HIV AIDS. 2010;5:269-76.
32. Curran JW, Jaffe HW, Hardy AM, Morgan WM, Selki RM, Dondero TJ. Epidemiology of HIV infection and AIDS in the United States. Science. 1988;239:610-6.
33. Hethcote HW, Van Ark JW. Epidemiological models for heterogeneous populations: proportionate mixing, parameter estimation, and immunization programs. Math Biosci. 1987;84:85-118.
34. Wiley JA, Herschkorn S, Padian N. Heterogeneity in the probability of HIV transmission per sexual contact. Stat Med. 1989;8:93-102.
35. Nonacs P, Kapheim KM. Modeling disease evolution with multilevel selection: HIV as a quasispecies social genome. J Evol Med. 2012;1:1.
36. Zintzaras E, Kowald A. A mathematical model of HIV dynamics in the presence of a rescuing virus with replication deficiency. Theory Biosci. 2011;130(2):127.
37. Yuan Y, Allen LJ. Stochastic models for virus and immune system dynamics. Math Biosci. 2011;234(2):84.
38. Mathieu E, Loup P, Dellamonica P, Daures JP. Markov modelling of immunological and virological states in HIV-1 infected patients. Biom J. 2005;47(6):834-46.
39. Hendriks JC, Satten GA, Longini IM, van Druten HA, Schellekens PT, Coutinho RA, van Griensven GJ. Use of immunological markers and continuous-time Markov models to estimate progression of HIV infection in homosexual men. AIDS. 1996;10(6):649-56.
40. Ruff CT, Ray SC, Kwon P, Zinn R, Pendleton A, Hutton N, Ashworth R, Gange S, Quinn TC, Siliciano RF, Persaud D. Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure. J Virol. 2002;76(18):9481-92.
41. Finzi D, Blankson J, Siliciano JD, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med. 1999;5:512-7.
42. Manner IW, Trøseid M, Oektedalen O, Baekken M, Os I. Low nadir CD4 cell count predicts sustained hypertension in HIV-infected individuals. J Clin Hypertens (Greenwich). 2013;15(2):101-6.
43. Kaufmann GR, Furrer H, Ledergerber B, Perrin L, Opravil M, Vernazza P, Cavassini M, Bernasconi E, Rickenbach M, Hirschel B, Battegay M, Swiss HIV Cohort Study. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin Infect Dis. 2005;41(3):361-72.
44. Baraboutis IG, Papastamopoulos V, Georgiou O, Skoutelis AT. Revertant multiresistant HIV in chronically infected drug naïve patients: when baseline resistance testing is not enough. Int J STD AIDS. 2007;18(10):722-4.
45. US Federal Funding for HIV/AIDS. The President's FY 2012 Budget, Kaiser Family Foundation HIV/AIDS Policy Fact Sheet; 2011.
46. Kates J. Spending on the HIV/AIDS epidemic: trends in U.S. spending on HIV/AIDS, Menlo Park, California. The Henry J. Kaiser Family Foundation; 2002.
47. Sanders GD, Bayoumi AM, Sundaram V, Bilir SP, Neukermans CP, Rydzak CE, Douglass LR, Lazzeroni LC, Holodniy M, Owens DK. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med. 2005;352(6):570-85.
48. Paltiel AD, Weinstein MC, Kimmel AD, et al. Expanded screening for HIV in the United States: an analysis of cost-effectiveness. N Engl J Med. 2005;352:586-95.
49. Walensky RP, Park JE, Wood R, Freedberg KA, Scott CA, Bekker LG, Losina E, Mayer KH, Seage GR 3rd, Paltiel AD. The cost-effectiveness of pre-exposure prophylaxis for HIV infection in South African women. Clin Infect Dis. 2012;54(10):4-13.
50. Desai K, Sansom SL, Ackers ML, Stewart SR, Hall HI, et al. Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness. AIDS. 2008;22:1829-39.
51. Paltiel AD, Freedberg KA, Scott CA, Schackman BR, Losina E, et al. HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis. 2009;48:806-15.
52. Freedberg KA, Losina E, Weinstein MC, Paltiel AD, Cohen CJ, Seage GR, Craven DE, Zhang H, Kimmel AD, Goldie SJ. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med. 2001;344(11):824-31.
53. Juusola JL, Brandeau ML, Owens DK, Bendavid E. The cost-effectiveness of pre-exposure prophylaxis for HIV prevention in the United States in men who have sex with men. Ann Intern Med. 2012;156:541-50.
54. Koppenhaver RT, Sorensen SW, Farnham PG, Sansom SL. The cost-effectiveness of pre-exposure prophylaxis in men who have sex with men in the United States: an epidemic model. J Acquir Immune Defic Syndr. 2011;58:e51-2.
55. Farnham PG, Holtgrave DR, Sansom SL, Hall HI. Medical costs averted by HIV prevention efforts in the United States, 1991-2006. JAIDS. 2010;54(5):565-7.
56. Braithwaite RS, Meltzer DO, King JT Jr, Leslie D, Roberts MS. What does the value of modern medicine say about the 50,000 per quality-adjusted life-year decision rule? Med Care. 2008;46(4):349-56.
57. Pierson R. WHO endorses use of HIV medicines for prevention. Chicago Tribune; 2012.
58. Keller SB, Smith DM. The price of tenofovir-emtricitabine undermines the cost-effectiveness and advancement of pre-exposure prophylaxis. AIDS. 2011;25(18):2308-10.
59. Waning B, et al. Temporal trends in generic and brand prices of antiretroviral medicines procured with donor funds in developing countries. J Generic Med. 2010;7(2):159-75.
60. Rayment M. Prevention of HIV-1 infection with early antiretroviral therapy. J Fam Plan Reprod Health Care. 2012;38:193.
61. Mermin J, Fenton KA. The future of HIV prevention in the United States. JAMA. 2012;308(4):347-8.
62. Williams B et al. Treatment as prevention: preparing the way. J Int AIDS Soc. 2010;14(1). http://www.avert.org/hiv-treatment-as-prevention.htm#sthash. QL8HClqI.dpuf.
63. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, Augustovski F, Briggs AH, Mauskopf J, Loder E, ISPOR Health Economic Evaluation Publication Guidelines-CHEERS Good Reporting Practices Task Force. Consolidated Health Economic Evaluation Reporting Standards (CHEERS). Value Health. 2013;16(2):231-50.